JPH06509710A - バキュロウイルスにおけるインフルエンザaのm2蛋白の改良発現及びm2蛋白の使用 - Google Patents
バキュロウイルスにおけるインフルエンザaのm2蛋白の改良発現及びm2蛋白の使用Info
- Publication number
- JPH06509710A JPH06509710A JP5503719A JP50371992A JPH06509710A JP H06509710 A JPH06509710 A JP H06509710A JP 5503719 A JP5503719 A JP 5503719A JP 50371992 A JP50371992 A JP 50371992A JP H06509710 A JPH06509710 A JP H06509710A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- baculovirus
- cells
- influenza
- expressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
Description
Claims (14)
- 1.DNA構築物であって、 i)インフルエンザAウイルスをコードしているDNAセグメント:ii)バキ ュロウイルスからの多角体遺伝子プロモーター、バキュロウイルス・ブランキン グ配列及びバクテリアの複製起点を含んで成るベクター、 を含んで成り、上記DNAセグメントが上記ベクターの多角体遺伝子プロモータ ーに作用可能な状態で結合されているDNA構築物。
- 2.前記のバキュロウイルス・プロモーターが、Autographa cal ifornicaの核多角体ウイルス・プロモーターである、請求項1に記載の DNA構築物。
- 3.前記のベクターが、pAcY1B1である、請求項1に記載のDNA構築物 。
- 4.インフルエンザAウイルスのM2をコードしている組み換えバキュロウイル ス。
- 5.前記のバキュロウイルス内でコードされている前記のM2の発現を可能にす るようなやり方で、請求項4に記載の前記の組み換えバキュロウイルスにより感 染した昆虫細胞。
- 6.Spodoptera frugiperda(Sf9)細胞である、請求 項5に記載の昆虫細胞。
- 7.バキュロウイルスにより発現されたインフルエンザAM2蛋白。
- 8.バキュロウイルスにより発現されたインフルエンザAM2蛋白の製造方法で あって、請求項5に記載の宿主細胞を、アマンタジン様薬物と共に、その宿主細 胞が前記のM2蛋白の増加した発現を示すような条件下で培養し、そしてそのM 2をその細胞から抽出することを含んで成る方法。
- 9.動物におけるインフルエンザの診断の免疫検定であって、以下の段階: i)表面を、請求項7のバキュロウイルス発現M2により被覆し;ii)上記の 被覆表面を、インフルエンザをもつ疑いのある動物からの生物学的サンプルと接 触させ;そして、iii)上記の蛋白と、上記の生物学的サンプル中に存在する それに好適な抗体との間に形成された複合体の存在の有無を検出すること、を含 んで成る免疫検定。
- 10.前記の表面が、免疫プロット又はウェスタン・プロットにより作られた、 ポリスチレン・マイクロタイトレーション・プレート、スライド又はナイロン若 しくはニトロセルロース膜である、請求項9に記載の免疫検定。
- 11.請求項7に記載のバキュロウイルス発現膜蛋白、及び生物学的サンプル中 のその蛋白に対する抗体の存在の有無を検出することにおける使用に好適である 補助的試薬を含んで成る診断キット。
- 12.インフルエンザA又はウイルスに対する、動物のためのワクチンであって 、そのウイルスに対する免疫化を誘導するのに十分な量の請求項7に記載のバキ ュロウイルス発現M2、及び医薬として許容される担体を含んで成るワクチン。
- 13.アジュバントをさらに含んで成る、請求項12に記載のワクチン。
- 14.好ましくない細胞を除去する治療的方法であって、以下の段階: (i)デリバリー系内でM2蛋白又は組み換えM2遺伝子を発現させ;(ii) 上記のデリバリー系を上記の好ましくない細胞に特異的に的中させ;そして、 (iii)上記の細胞に与えられた一定量のアマンタジン様薬物によりその細胞 の細胞毒性効果を調節すること、を含んで成る方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US738,032 | 1991-07-31 | ||
US07/738,032 US5290686A (en) | 1991-07-31 | 1991-07-31 | Expression of influenza a M2 protein in baculovirus |
PCT/US1992/006316 WO1993003173A1 (en) | 1991-07-31 | 1992-07-29 | Improved expression of influenza a m2 protein in baculovirus and uses of m2 protein |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06509710A true JPH06509710A (ja) | 1994-11-02 |
Family
ID=24966293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5503719A Expired - Lifetime JPH06509710A (ja) | 1991-07-31 | 1992-07-29 | バキュロウイルスにおけるインフルエンザaのm2蛋白の改良発現及びm2蛋白の使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5290686A (ja) |
EP (1) | EP0597008A4 (ja) |
JP (1) | JPH06509710A (ja) |
AU (1) | AU659867B2 (ja) |
CA (1) | CA2111116A1 (ja) |
WO (1) | WO1993003173A1 (ja) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU711163B2 (en) * | 1995-07-21 | 1999-10-07 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The | Method for the quantitative measurement of human acute phase serum amyloid a protein; recombinant protein; specific antibody |
US7157089B1 (en) * | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
GB9815040D0 (en) * | 1998-07-10 | 1998-09-09 | Medical Res Council | Conditional mutant |
US20030219442A1 (en) * | 2002-03-13 | 2003-11-27 | Toshifumi Mikayama | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
ES2217967B1 (es) * | 2003-03-31 | 2006-01-01 | Consejo Sup. Investig. Cientificas | Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv. |
ES2307345B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
ES2307346B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
US8778880B2 (en) * | 2004-02-02 | 2014-07-15 | Ambrx, Inc. | Human growth hormone modified at position 35 |
CA2568952C (en) * | 2004-06-18 | 2019-05-21 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
WO2006019955A2 (en) * | 2004-07-14 | 2006-02-23 | President And Fellows Of Harvard College | Antiviral methods and compositions |
WO2006091231A2 (en) * | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
US20060135933A1 (en) * | 2004-12-21 | 2006-06-22 | Newlin Seth M | Stretchable absorbent article featuring a stretchable segmented absorbent |
ATE541934T1 (de) * | 2004-12-22 | 2012-02-15 | Ambrx Inc | Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon |
DK2399893T3 (en) | 2004-12-22 | 2018-10-08 | Ambrx Inc | COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES |
AU2005322019B2 (en) | 2004-12-22 | 2010-08-26 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
KR20070090023A (ko) | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | 변형 인간 성장 호르몬 |
SG161210A1 (en) * | 2004-12-22 | 2010-05-27 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
EP1893229B1 (en) * | 2005-06-03 | 2011-10-19 | Ambrx, Inc. | Improved human interferon molecules and their uses |
ES2310062B1 (es) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
US7632823B2 (en) * | 2005-08-18 | 2009-12-15 | Ambrx, Inc. | Compositions of tRNA and uses thereof |
RS51998B (en) * | 2005-11-08 | 2012-04-30 | Ambrx Inc. | ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES |
WO2007059312A2 (en) * | 2005-11-16 | 2007-05-24 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
EP1968635B1 (en) * | 2005-12-14 | 2014-09-17 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
EP1991264B1 (en) | 2006-03-07 | 2015-01-07 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
KR20090051227A (ko) * | 2006-09-08 | 2009-05-21 | 암브룩스, 인코포레이티드 | 척추동물 세포를 위한 하이브리드 서프레서 tRNA |
AU2007292893B2 (en) * | 2006-09-08 | 2012-03-01 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
JP5840345B2 (ja) * | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用 |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US8080645B2 (en) * | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US20090098527A1 (en) * | 2006-09-12 | 2009-04-16 | Fischer Gerald W | Biological organism identification product and methods |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US8003314B2 (en) | 2007-04-16 | 2011-08-23 | Diagnostic Hybrids, Inc. | Methods for direct fluorescent antibody virus detection in liquids |
CA2685596A1 (en) * | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
EP3058954B1 (en) | 2007-08-27 | 2017-03-01 | Longhorn Vaccines and Diagnostics, LLC | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
ES2552858T3 (es) | 2007-10-01 | 2015-12-02 | Longhorn Vaccines And Diagnostics, Llc | Recogida de muestras biológicas y sistema de transporte y métodos de uso |
WO2009055010A2 (en) * | 2007-10-25 | 2009-04-30 | President And Fellows Of Harvard College | Systems and methods for studying influenza |
JP5547083B2 (ja) | 2007-11-20 | 2014-07-09 | アンブルックス,インコーポレイテッド | 修飾されたインスリンポリペプチドおよびそれらの使用 |
NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
SG190562A1 (en) | 2008-04-18 | 2013-06-28 | Vaxinnate Corp | Deletion mutants of flagellin and methods of use |
PE20110426A1 (es) | 2008-07-23 | 2011-07-01 | Ambrx Inc | Polipeptidos g-csf bovinos modificados |
KR101647164B1 (ko) | 2008-09-26 | 2016-08-09 | 암브룩스, 인코포레이티드 | 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도 |
MX357314B (es) * | 2008-09-26 | 2018-07-04 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. |
WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
SG181769A1 (en) | 2009-12-21 | 2012-07-30 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
US20130115237A1 (en) | 2010-06-09 | 2013-05-09 | Vaccine Technologies, Incorporated | Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment |
EP2605789B1 (en) | 2010-08-17 | 2019-06-05 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
EP3494989A1 (en) | 2012-01-26 | 2019-06-12 | Longhorn Vaccines and Diagnostics, LLC | Composite antigenic sequences and vaccines |
CN114805532A (zh) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
AU2018219283B2 (en) | 2017-02-08 | 2022-05-19 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
CN115466710A (zh) * | 2021-06-11 | 2022-12-13 | 舒泰神(北京)生物制药股份有限公司 | 一种获得无病毒细胞系的方法及其所获得的无病毒细胞系 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3922617A (en) * | 1974-11-18 | 1975-11-25 | Cutler Hammer Inc | Adaptive feed forward system |
US4879519A (en) * | 1988-10-31 | 1989-11-07 | American Telephone And Telegraph Company, At&T Bell Labs | Predistortion compensated linear amplifier |
-
1991
- 1991-07-31 US US07/738,032 patent/US5290686A/en not_active Expired - Fee Related
-
1992
- 1992-07-29 CA CA002111116A patent/CA2111116A1/en not_active Abandoned
- 1992-07-29 EP EP92917007A patent/EP0597008A4/en not_active Withdrawn
- 1992-07-29 AU AU24056/92A patent/AU659867B2/en not_active Ceased
- 1992-07-29 JP JP5503719A patent/JPH06509710A/ja not_active Expired - Lifetime
- 1992-07-29 WO PCT/US1992/006316 patent/WO1993003173A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3922617A (en) * | 1974-11-18 | 1975-11-25 | Cutler Hammer Inc | Adaptive feed forward system |
US4879519A (en) * | 1988-10-31 | 1989-11-07 | American Telephone And Telegraph Company, At&T Bell Labs | Predistortion compensated linear amplifier |
Also Published As
Publication number | Publication date |
---|---|
EP0597008A4 (en) | 1997-03-19 |
US5290686A (en) | 1994-03-01 |
AU659867B2 (en) | 1995-06-01 |
CA2111116A1 (en) | 1993-02-18 |
AU2405692A (en) | 1993-03-02 |
WO1993003173A1 (en) | 1993-02-18 |
EP0597008A1 (en) | 1994-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06509710A (ja) | バキュロウイルスにおけるインフルエンザaのm2蛋白の改良発現及びm2蛋白の使用 | |
Jia et al. | Roles of African swine fever virus structural proteins in viral infection | |
US10258686B2 (en) | Materials and methods for respiratory disease control in canines | |
US5316910A (en) | Bioassay for influenza A and B nucleoprotein | |
Richt et al. | Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine | |
DK170948B1 (da) | Ikke naturligt forekommende pseudorabiesvirus, vaccine indeholdende dette virus samt fremgangsmåde til serologisk skelnen mellem inficerede og vaccinerede dyr | |
CN116333161B (zh) | 一种covid-19亚单位疫苗及其制备方法与应用 | |
US10545148B2 (en) | Marker system, in particular for baculovirus-expressed subunit antigens | |
CN101253267A (zh) | 用于犬科动物中呼吸系统疾病控制的物质和方法 | |
CN101563361A (zh) | 能够感染犬科动物的流感病毒及其用途 | |
Jin et al. | Development of enzyme-linked immunosorbent assay with nucleoprotein as antigen for detection of antibodies to avian influenza virus | |
Russell et al. | Duration of protective immunity and antibody responses in cattle immunised against alcelaphine herpesvirus-1-induced malignant catarrhal fever | |
Bahgat et al. | Characterization of an avian influenza virus H5N1 Egyptian isolate | |
Robalino et al. | Inactivation of white spot syndrome virus (WSSV) by normal rabbit serum: implications for the role of the envelope protein VP28 in WSSV infection of shrimp | |
KR20100139096A (ko) | 조성물, 방법 및 키트 | |
Liu et al. | Development and evaluation of an avian influenza, neuraminidase subtype 1, indirect enzyme-linked immunosorbent assay for poultry using the differentiation of infected from vaccinated animals control strategy | |
CN109563491A (zh) | 新颖的副粘病毒及其用途 | |
Lee et al. | Immunogenicity of Japanese encephalitis virus envelope protein by Hyphantria cunea nuclear polyhedrosis virus vector in guinea pig | |
US5106965A (en) | Detection of human adenovirus | |
KR101339162B1 (ko) | 돼지 인플루엔자 바이러스 감염의 예방 또는 치료방법 | |
TWI776097B (zh) | 增強免疫力或抗病力的食品添加劑 | |
CN113444155B (zh) | MERS-CoV膜蛋白受体结合域二聚体及其编码基因和应用 | |
US20230058789A1 (en) | Sars-cov-2 chimeric vlp vaccine composition, expressing vector and use thereof | |
CN113121656B (zh) | EBV包膜糖蛋白gp350抗原表位及其单克隆抗体 | |
US20230398201A1 (en) | Gene shuffled lyssavirus vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081003 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081003 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091003 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101003 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 14 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 14 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 14 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121003 Year of fee payment: 15 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121003 Year of fee payment: 15 |